multiple agendas attempting to reduce the overall available of controlled meds

The common denominator on all these attacks on the availability of control meds is our JUDICIAL SYSTEM. Starting when 41 state Attorney Generals, that sued the 3 major drug wholesalers, and got them to agree: to pay billions in fines – didn’t even go to court – AND agreed to REDUCE the controls that they sell to ALL PHARMACIES. Here is a synopsis of the nearly 600 page agreement:  AGREEMENT  via the “grapevine”, this agreement was signed in April 2022 and was not suppose to see the light of day, but someone leaked it in early 2023. The “grapevine” also states that those same AGs got the major pharmacy chains to pay billions in fines and agreed to reduce the controlled Rxs filled, but that agreement has not seen the light of day yet. There was also some sort of agreement with Kroger and some sort of fine being paid, but another agreement that may not have seen the light of day.

DEA revokes the DEA license of Shreveport, Louisiana-based Morris & Dickson, the nation’s fourth-largest wholesale drug distributor, with $4 billion a year in revenue and nearly 600 employees serving pharmacies and hospitals in 29 states.  https://www.usnews.com/news/best-states/louisiana/articles/2023-05-26/after-yearslong-delay-dea-revokes-license-of-wholesale-drug-distributor-over-opioid-crisis-failures  What is going to happen to the allocation of the controlled meds that this wholesaler had? Will they JUST DISAPPEAR?

Then we have Rite Aid filing for bankruptcy and closing 100+ stores and both CVS & Walgreen is scheduled to close 100+ stores each over the coming years. https://www.pharmaciststeve.com/drugstore-closures-could-make-pharmacy-deserts-even-worse/  If history repeats itself, these chains will just transfer the Rx files to one of their nearby store, but happens to the controlled meds allocated to these closed stores?  Again, will they just disappear?

Is the current DEA proposal for reducing pharma opioid production quotas, just a “smoke screen” for what various parts of our judicial system has already enacted or is in the process of enacting?  https://www.pharmaciststeve.com/dea-proposed-reduction-in-pharma-controlled-med-production-quotas/

Earlier this year, the DEA stated that <1% of pharmas’ opioids are diverted. Historically, the estimated number of chronic pain pts in the USA as a percentage of our population…has remained fairly constant. However, during the 2010-2020 decade our population grew at about 11%, the same\similar time frame that the vast majority of opioid/controlled med pharma production quotas were reduced somewhere in the 50% range.

Is this some sort of WARPED covert genocide?  Getting chronic pain pts to die prematurely from under/untreated pain and or end up committing suicide?

Opioid Litigation Affects All of Pharmacy

https://www.daily-remedy.com/opioid-litigation-affects-all-of-pharmacy/

Opioid litigation has had a significant impact on the number of pharmacies operating within the United States. This has occurred due to several reasons.

Firstly, opioid litigation involves lawsuits and legal actions against pharmaceutical companies, distributors, and even pharmacies themselves, holding them accountable for their role in the opioid crisis. These litigations have resulted in substantial financial penalties and settlements for the defendants, often in the billions of dollars. As a consequence, many pharmacies have faced financial strain and even bankruptcy, leading to a reduction in the overall number of pharmacies.

Secondly, the legal actions and subsequent reforms brought about by opioid litigation have significantly strengthened regulatory oversight of pharmacies. Government agencies such as the Drug Enforcement Administration (DEA) and state regulatory bodies have implemented stricter regulations and monitoring systems to combat the over-prescription and misuse of opioids. These regulations often require pharmacies to implement more comprehensive prescribing and dispensing practices, which can be costly and burdensome for smaller or less compliant pharmacies. As a result, some pharmacies have found it economically unviable to continue operating, leading to a decrease in the number of pharmacies.

Additionally, opioid litigation has resulted in heightened public awareness and scrutiny surrounding the role of pharmacies in the opioid crisis. This increased awareness has caused some individuals and communities to seek alternatives for pain management, leading to a decrease in demand for opioids and consequently reducing the need for pharmacies to dispense these medications. This shift in consumer behavior has further contributed to a decline in the number of pharmacies specializing in opioids.

Moreover, opioid litigation has brought about changes in the attitudes and practices of healthcare providers. Many physicians and healthcare professionals have become more cautious and vigilant when prescribing opioids, resulting in decreased prescription rates. As a consequence, pharmacies that solely relied on opioid prescriptions for their business may have faced a decline in demand, making it financially unsustainable for them to continue operating.

Lastly, the negative publicity and social stigma surrounding opioids have influenced consumer perceptions and choices concerning pharmacies. As the opioid crisis garners significant media attention, consumers have become more discerning about where they fill their prescriptions. Some individuals may actively seek out pharmacies that are not involved in legal actions or that focus on alternative pain management options. This consumer shift in preference has created a disadvantage for pharmacies with a history of opioid-related litigation, leading to a decrease in their customer base and overall viability.

In conclusion, opioid litigation has caused a decline in the number of pharmacies due to financial pressures, increased regulatory oversight, decreased demand for opioids, changes in prescribing practices, and consumer preferences. These combined factors have significantly impacted the pharmacy landscape within the United States, leading to a reduction in the overall number of operating pharmacies.

 

4 Responses

  1. It’s isn’t impossible to get past sovereign immunity; I’ve forgotten the details. It is unlikely. But no one will be able to fill regular prescriptions either at the closing pharmacies, and what’s left will be insufficient to cover demand. This will create chaos. I thought to try to identify which hadn’t been been involved in litigation, then realized I might be better off sticking with seniority at old pharmacy. Steve, do you know pharmacies not involved? Thank you so much!

  2. Welcome to the pure definition of,,,”Evinced by design,to absolute despotism,”,,,,,,,maryw

  3. Could these pharmacies that had to go out of business then sue the DEA/DOJ for restricting their business?

    • all bureaucrats are protected by sovereign immunity and you can only sue them if they agreed to let you…BUT… you cannot get any monetary damages from suing them.. at most … the courts may agree that they caused financial harm.

Leave a Reply

Discover more from PHARMACIST STEVE

Subscribe now to keep reading and get access to the full archive.

Continue reading